Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Annexon, Inc. (ANNX)  
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30


Download
   
Exchange: N/A
Security Type: N/A
Shares Out: 86,097,000
Market Cap: N/A
Last Volume: 0 Avg Vol: 0
52 Week Range: $ - $
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

                 
 
Company Profile   Annexon is a clinical-stage biopharmaceutical company developing a class of complement medicines designed to stop the classical complement pathway at its start, C1q, in order to bring therapies to patients suffering from serious complement-mediated autoimmune, neurodegenerative and ophthalmic disorders. Co. is developing a pipeline of product candidates designed to block the activity of C1q and the entire classical complement pathway for a range of complement-mediated diseases. Co.'s pipeline includes three clinical-stage assets across three therapeutic franchises: autoimmune, neurodegenration and ophtamology. Co. its developing its primary candidate, ANX005.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 3,200 353,200 653,200 5,754,246
Total Buy Value $19,411 $1,027,411 $1,667,131 $29,090,439
Total People Bought 1 2 3 3
Total Buy Transactions 1 2 3 5
Total Shares Sold 17,898 59,898 62,990 73,114
Total Sell Value $98,919 $288,851 $300,713 $361,680
Total People Sold 4 4 4 4
Total Sell Transactions 7 9 12 17
End Date 2024-01-18 2023-10-17 2023-04-18 2022-04-18

   
Records found: 83
  Page 1 of 4  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Carson William H.   –       •      –    2024-04-08 4 AB $6.07 $19,411 D/D 3,200 3,200     -
   Yednock Ted EVP & CHIEF INNOVATION OFFICER   •       –      –    2024-02-20 4 S $5.51 $14,348 D/D (2,604) 72,471     -
   Overdorf Michael EVP & CHIEF BUSINESS OFFICER   •       –      –    2024-02-20 4 S $5.48 $10,691 D/D (1,951) 85,641     -
   Lew Jennifer EVP & CHIEF FINANCIAL OFFICER   •       –      –    2024-02-20 4 S $5.53 $14,339 D/D (2,593) 82,058     -
   Yednock Ted EVP & CHIEF INNOVATION OFFICER   •       –      –    2024-02-16 4 A $0.00 $0 D/D 39,000 75,075     -
   Overdorf Michael EVP & CHIEF BUSINESS OFFICER   •       –      –    2024-02-16 4 A $0.00 $0 D/D 39,000 87,592     -
   Lew Jennifer EVP & CHIEF FINANCIAL OFFICER   •       –      –    2024-02-16 4 A $0.00 $0 D/D 39,000 84,651     -
   Dananberg Jamie CHIEF MEDICAL OFFICER   •       –      –    2024-02-16 4 A $0.00 $0 D/D 39,000 39,000     -
   Artis Dean Richard EVP & CHIEF SCIENTIFIC OFFICER   •       –      –    2024-02-16 4 A $0.00 $0 D/D 39,000 89,329     -
   Overdorf Michael EVP & CHIEF BUSINESS OFFICER   •       –      –    2024-02-12 4 S $5.53 $7,460 D/D (1,349) 48,592     -
   Lew Jennifer EVP & CHIEF FINANCIAL OFFICER   •       –      –    2024-02-12 4 S $5.54 $10,022 D/D (1,809) 45,651     -
   Love Douglas PRESIDENT AND CEO   •       •      –    2024-02-12 4 S $5.54 $32,032 D/D (5,782) 196,121     -
   Yednock Ted EVP & CHIEF INNOVATION OFFICER   •       –      –    2024-02-12 4 S $5.54 $10,027 D/D (1,810) 36,075     -
   Yednock Ted EVP & Chief Innovation Officer   •       –      –    2023-12-27 4/A AS $4.52 $94,966 D/D (21,000) 37,885     -
   Yednock Ted EVP & Chief Innovation Officer   •       –      –    2023-12-27 4/A OE $1.41 $34,176 D/D 21,000 58,885     -
   Yednock Ted EVP & Chief Innovation Officer   •       –      –    2023-12-27 4 AS $4.52 $94,966 D/D (21,000) 0     -
   Yednock Ted EVP & Chief Innovation Officer   •       –      –    2023-12-27 4 OE $1.41 $34,176 D/D 21,000 21,000     -
   Satter Muneer A Director   –       •       •   2023-12-26 4 B $2.88 $1,008,000 I/I 350,000 7,406,024 2.25     -
   Lew Jennifer EVP & Chief Financial Officer   •       –      –    2023-07-11 4 S $3.84 $4,055 D/D (1,057) 47,460     -
   Yednock Ted EVP & Chief Innovation Officer   •       –      –    2023-07-11 4/A AS $3.84 $4,055 D/D (1,057) 37,885     -
   Overdorf Michael EVP & Chief Business Officer   •       –      –    2023-07-11 4 S $3.84 $3,752 D/D (978) 45,802     -
   Bcip Life Sciences Associates, Lp 10% Owner   –       –       •   2023-05-25 3 IO $0.00 $0 I/I 0 5,401,926     -
   Bcip Life Sciences Associates, Lp 10% Owner   –       –       •   2023-05-25 4 B $2.13 $639,720 I/I 300,000 5,701,926 1.5     -
   Yednock Ted EVP & Chief Innovation Officer   •       –      –    2023-03-16 3 IO $0.00 $0 I/I 0 21,000     -
   Yednock Ted EVP & Chief Innovation Officer   •       –      –    2023-03-16 3 IO $0.00 $0 D/D 0 38,942     -
  83 Records found
  1  2  3  4   
  Page 1 of 4
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us